PT - JOURNAL ARTICLE AU - Luo, Yiming AU - Ferrada, Marcela A AU - Sikora, Keith A AU - Rankin, Cameron AU - Alessi, Hugh D AU - Kastner, Daniel L AU - Deng, Zuoming AU - Zhang, Mengqi AU - Merkel, Peter A AU - Kraus, Virginia B AU - Allen, Andrew S AU - Grayson, Peter C TI - Ultra-rare genetic variation in relapsing polychondritis: a whole-exome sequencing study AID - 10.1136/ard-2023-224732 DP - 2024 Feb 01 TA - Annals of the Rheumatic Diseases PG - 253--260 VI - 83 IP - 2 4099 - http://ard.bmj.com/content/83/2/253.short 4100 - http://ard.bmj.com/content/83/2/253.full SO - Ann Rheum Dis2024 Feb 01; 83 AB - Objective Relapsing polychondritis (RP) is a systemic inflammatory disease of unknown aetiology. The objective of this study was to examine the contribution of rare genetic variations to RP.Methods We performed a case–control exome-wide rare variant association analysis that included 66 unrelated European American cases with RP and 2923 healthy controls (HC). Gene-level collapsing analysis was performed using Firth’s logistics regression. Exploratory pathway analysis was performed using three different methods: Gene Set Enrichment Analysis, sequence kernel association test and higher criticism test. Plasma DCBLD2 levels were measured in patients with RP and HC using ELISA.Results In the collapsing analysis, RP was associated with a significantly higher burden of ultra-rare damaging variants in the DCBLD2 gene (7.6% vs 0.1%, unadjusted OR=79.8, p=2.93×10−7). Plasma DCBLD2 protein levels were significantly higher in RP than in HC (median 4.06 ng/µL vs 0.05 ng/µL, p<0.001). The pathway analysis revealed a statistically significant enrichment of genes in the tumour necrosis factor signalling pathway driven by rare damaging variants in RELB, RELA and REL using higher criticism test weighted by eigenvector centrality.Conclusions This study identified specific rare variants in the DCBLD2 gene as a putative genetic risk factor for RP. These findings should be validated in additional patients with RP and supported by future functional experiments.Data are available upon reasonable request.